Follistatin-315

Follistatin-315 (FS-315) is the soluble 315-amino-acid isoform of natural follistatin. Follistatin is encoded by the FST gene and produced through alternative splicing into multiple isoforms, with FS-288 (membrane-bound through GPI anchor in some contexts), FS-315 (soluble plasma form), and FS-344 (heparan sulfate-binding form that becomes membrane-associated through cell-surface proteoglycans) as the principal isoforms. FS-315 lacks the heparin-binding C-terminal acidic region present in FS-344 and circulates more freely in plasma.

Follistatin's biological role is as a high-affinity binder of activin A, with secondary binding to myostatin (GDF-8), GDF-11, BMP-2, BMP-4, BMP-6, and BMP-7. Binding sequesters these ligands and prevents their interaction with cell-surface receptors. The result is broad inhibition of TGF-beta superfamily signaling that affects muscle mass regulation, fertility, fibrosis, hematopoiesis, and other processes.

The interest in follistatin for muscle therapy derives from its high-affinity binding to myostatin. Loss-of-function mutations in myostatin produce the Belgian Blue cattle muscle-hypertrophy phenotype and corresponding effects in myostatin-knockout mice. Increasing follistatin levels increases functional myostatin neutralization and supports muscle hypertrophy. This has been pursued through:

1. Recombinant follistatin protein administration (research-chemical and preclinical work)
2. AAV gene therapy delivering follistatin sequences to muscle (clinical development by Milo Biotechnology and Sarepta Therapeutics)

The Evidence

Animal models. Recombinant follistatin and follistatin gene therapy have produced substantial muscle hypertrophy in mice, rats, dogs, and non-human primates. The Kota et al., 2009 study documented sustained muscle growth in non-human primates after AAV-delivered follistatin gene transfer, supporting translation to human trials.

Mendell et al., 2015. AAV-mediated follistatin gene therapy in Becker muscular dystrophy patients. The trial used the FS-344 isoform delivered intramuscularly. Some patients showed improvements in functional measures (6-minute walk distance) and muscle histology. The trial established proof of concept for follistatin gene therapy in muscular dystrophy but did not establish clinical efficacy meeting Phase 3 standards.

Subsequent clinical work has continued with various AAV-delivered follistatin programs. The Milo Biotechnology / Sarepta program has explored dose escalation and indication expansion. As of May 2026, no Phase 3 trial completion or FDA approval has been reported.

Sidis et al., 2006. Comparative biological activity of follistatin isoforms, characterizing the differences between FS-315 and FS-344 in ligand binding and cellular effects.

Recombinant peptide research-chemical use is documented through anecdotal user reports without controlled studies. The recombinant FS-315 form has minimal published clinical research compared with the AAV gene therapy programs.

Regulatory and Legal Status

FDA. No approval for recombinant FS-315. AAV follistatin gene therapy programs have IND status without approved indication as of May 2026.

EMA. No approval.

Compounding. Not on FDA bulk drug substances list.

WADA. Prohibited at all times under Section S4.4 (Inhibitors of myostatin function and other related substances).

Research-chemical availability. Some vendors offer Follistatin-315-labeled recombinant protein. Identity verification is the buyer's responsibility; production quality varies widely.

Follistatin-315 is a soluble ligand-binding protein that neutralizes multiple TGF-beta superfamily ligands.

Activin A binding. The highest affinity follistatin interaction is with activin A, with Kd in the picomolar range. Two follistatin molecules wrap around an activin dimer, completely covering the type I and type II receptor binding interfaces and preventing receptor engagement. The activin neutralization affects pituitary FSH regulation, fertility, hematopoiesis, and inflammatory responses.

Myostatin binding. Follistatin binds myostatin (GDF-8) with high affinity, neutralizing its signaling at ActRIIB and downstream type I receptors. Myostatin neutralization removes a major brake on muscle growth, producing the muscle hypertrophy that motivates therapeutic interest.

Other ligand binding. Follistatin also binds GDF-11, BMP-2, BMP-4, BMP-6, and BMP-7 with varying affinities. The broad binding profile produces a more complex pharmacology than selective myostatin inhibitors.

FS-315 vs FS-344 differences. Both isoforms have similar affinity for activin A and myostatin. The C-terminal acidic region present in FS-344 binds cell-surface heparan sulfate proteoglycans, anchoring the protein at tissue surfaces. FS-315 lacks this domain and circulates more freely in plasma. The functional consequence is that FS-315 produces more systemic effects while FS-344 acts more locally at heparan sulfate-rich tissue surfaces.

Downstream consequences of broad TGF-beta superfamily inhibition:

• Muscle hypertrophy through myostatin neutralization
• Effects on pituitary FSH regulation through activin neutralization
• Effects on hematopoiesis and red blood cell production
• Effects on inflammation and fibrosis pathways
• Potential effects on vascular function through BMP-9 and BMP-10 binding (raising the safety concern flagged by the ACE-031 program halt)

Pharmacokinetics. Specific human PK data for recombinant FS-315 is not available. The natural plasma half-life of endogenous follistatin is short (minutes to hours), but the binding to ligands extends the functional half-life of inhibition. AAV gene therapy provides sustained transgene expression for months to years from a single administration.

Animal model and clinical-trial effects:

• Substantial muscle hypertrophy in animal models (mice, rats, dogs, primates)
• Functional improvements in some patients in Becker muscular dystrophy gene-therapy trials
• Effects on body composition (increased lean mass, decreased fat mass) in some preclinical work
• Strength improvements in animal protocols
• Cardiac and pulmonary safety in primate and limited human studies

Research-chemical user reports of recombinant FS-315 describe muscle mass gains and strength improvements. Reports are anecdotal, uncontrolled, and not verified for vial identity. Recombinant protein production at non-pharmaceutical-grade facilities raises concerns about purity, endotoxin contamination, and biological activity verification.

No standardized human dosing protocol exists for off-label recombinant FS-315 use.

Research-chemical user protocols typically use 100 to 500 mcg per day subcutaneous over multi-week cycles. These doses are based on rodent body-surface-area scaling and informal community experience; they lack clinical pharmacokinetic support.

Clinical AAV gene therapy programs use intramuscular injection of viral vectors delivering follistatin transgenes. The doses are measured in viral genome copies rather than protein mass, and the delivery mechanism is fundamentally different from recombinant protein administration.

The mismatch between research-chemical recombinant protein use and clinical gene-therapy approaches means that user-protocol extrapolation from clinical trial data is methodologically problematic.

Animal toxicology has reported muscle hypertrophy as the primary effect with limited dose-limiting toxicity in published studies. Long-term human safety data for systemic FS-315 administration is limited.

Theoretical concerns based on mechanism and class:

• Vascular effects through BMP-9 and BMP-10 binding; the ACE-031 program halt for bleeding events linked to these ligands raises analogous concerns for follistatin
• Fertility and pituitary effects through activin A binding; activin A is a critical regulator of FSH secretion
• Hematopoietic effects from activin and BMP pathway inhibition
• Effects on inflammation and immunity with chronic broad TGF-beta superfamily inhibition
• Effects in pregnancy are concerning; activin A and BMP signaling are critical for embryonic development
• Tendon function and injury risk with rapid muscle hypertrophy outpacing tendon adaptation

The broad TGF-beta superfamily binding profile of follistatin creates more potential for off-target effects than selective myostatin inhibitors. The ACE-031 program experience documents that broad inhibition of related ligands can produce clinically significant adverse events.

For users considering research-chemical FS-315, the safety considerations include all the mechanism-based theoretical concerns plus identity and purity risks of non-pharmaceutical-grade recombinant protein.

Follistatin-315 is in the myostatin-pathway inhibitor category. The closest peers in research-chemical and clinical development:

• Follistatin-344 — Heparan sulfate-binding isoform with different tissue distribution
• ACE-031 — Acceleron's soluble ActRIIB-Fc decoy receptor, development halted for bleeding events
• Bimagrumab — ActRII antibody, encountered safety signals in trials
• Apitegromab — More myostatin-selective antibody, advancing in spinal muscular atrophy trials
• Domagrozumab — Myostatin antibody, discontinued in DMD development

For muscle anabolism research-chemical stacks, follistatin is sometimes combined with MGF, IGF-1 LR3, or IGF-1 DES for parallel pathway effects. None of these combinations has been studied in controlled settings, and combination protocols compound safety risks rather than confirming benefit.

External pharmaceutical comparators for muscle-wasting indications:

• For Duchenne and Becker muscular dystrophy: corticosteroids (deflazacort, prednisone), exon-skipping antisense oligonucleotides (eteplirsen, golodirsen, viltolarsen, casimersen), gene therapy (elevidys/delandistrogene moxeparvovec)
• For spinal muscular atrophy: nusinersen (Spinraza), onasemnogene abeparvovec (Zolgensma), risdiplam (Evrysdi), apitegromab (myostatin antibody, advancing in late-stage trials)
• For sarcopenia and age-related muscle loss: no FDA-approved pharmacotherapy; resistance training plus adequate protein intake remain first-line evidence-based approaches
• For cancer cachexia: anamorelin (approved in Japan but not US), supportive care interventions

Follistatin-315 has no comparable evidence base for any specific muscle-wasting indication and is not a substitute for evidence-based care.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.